文献速递前列腺癌

多学科方法应对非转移性去势抵抗性前列腺癌患者管理中未满足的需求

A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-03-02

本文由10位前列腺癌多学科专家组成的小组,通过文献回顾与讨论,针对非转移性去势抵抗性前列腺癌(nmCRPC)管理和监测中的未满足需求制定共识建议。专家指出,第二代雄激素受体抑制剂(SGARI)在临床试验中较安慰剂延长了无转移生存期(MFS)、总生存期(OS)并改善患者生活质量,但药物间短期和长期安全性特征及药物相互作用存在重要差异;相当比例使用SGARI的患者可能在PSA未升高的情况下出现疾病进展,提示除PSA监测外需加强影像学检查;新型前列腺特异性膜抗原正电子发射断层扫描放射性示踪剂较传统影像学检测疾病准确性更高。多学科团队可确保nmCRPC患者获得最佳和个体化的疾病管理。

要点

  • SGARI(阿帕他胺、恩扎卢坦、达罗他胺)较安慰剂延长nmCRPC患者的MFS、OS并改善生活质量。
  • 各SGARI间MFS和OS总体相当,但短期和长期药物安全性特征及药物相互作用存在重要差异。
  • 相当比例使用SGARI的患者可在PSA未升高的情况下出现疾病进展,提示除PSA监测外需加强影像学检查。

核心结论

  • nmCRPC的临床决策已变得更加复杂,为精准医学应用于患者管理提供了新机会。
  • 多学科团队可确保nmCRPC患者获得最佳和个体化的疾病管理。

研究设计与样本

  • 由10位前列腺癌多学科专家组成的小组对nmCRPC患者管理和监测中的未满足需求进行文献回顾和讨论,以制定共识建议。

主要发现

  • 在SGARI临床试验中,阿帕他胺、恩扎卢坦、达罗他胺较安慰剂延长了MFS、OS并改善患者生活质量。
  • 各SGARI治疗的患者MFS和OS总体相当,但短期和长期药物安全性特征及药物相互作用存在重要差异。
  • 相当比例使用SGARI的患者可能在PSA未升高的情况下出现疾病进展。
  • 新型前列腺特异性膜抗原正电子发射断层扫描放射性示踪剂较传统影像学检测疾病准确性更高。

临床怎么用

  • 多学科团队可确保nmCRPC患者获得最佳和个体化的疾病管理(作者结论)。
  • 除PSA监测外,需加强影像学检查以追踪疾病进展(作者结论)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: With the availability of second-generation androgen receptor inhibitors (SGARIs), the treatment landscape has changed dramatically for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). In clinical trials, the SGARIs (apalutamide, enzalutamide, darolutamide) increased metastasis-free survival (MFS), overall survival (OS), and patient quality of life compared to placebo. These drugs were subsequently integrated into nmCRPC clinical practice guidelines. With advances in radiographic imaging, disease assessment, and patient monitoring, nmCRPC strategies are evolving to address limitations related to tracking disease progression using prostate-specific antigen (PSA) kinetics. METHODS: A panel of 10 multidisciplinary experts in prostate cancer conducted reviews and discussions of unmet needs in the management and monitoring of patients with nmCRPC in order to develop consensus recommendations. RESULTS: Across the SGARI literature, patient MFS and OS are generally comparable for all treatments, but important distinctions exist regarding short- and long-term drug safety profiles and drug-drug interactions. With respect to disease monitoring, a substantial proportion of patients using SGARIs may experience disease progression without rising PSA levels, suggesting a need for enhanced radiographic imaging in addition to PSA monitoring. Recent data also indicate that novel prostate-specific membrane antigen positron emission tomography radiotracers provide enhanced accuracy for disease detection, as compared to conventional imaging. CONCLUSIONS: Clinical decision-making in nmCRPC has become more complex, with new opportunities to apply precision medicine to patient care. Multidisciplinary teams can ensure that patients with nmCRPC receive optimal and individualized disease management.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Shore ND, Antonarakis ES, Ross AE, et al. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38431761. doi:10.1038/s41391-024-00803-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。